| Does the median voter model explain the size of government?: Evidence from the states M Gouveia, NA Masia Public Choice 97 (1-2), 159-177, 1998 | 147 | 1998 |
| Vaccination and GDP growth rates: Exploring the links in a conditional convergence framework NA Masia, J Smerling, T Kapfidze, R Manning, M Showalter World Development 103, 88-99, 2018 | 32 | 2018 |
| Exploring the potential link between Medicaid access restrictions, physician location, and health disparities A Headen, N Masia Am J Manag Care 11 (spec no), SP21-SP26, 2005 | 20 | 2005 |
| Effects of profit‐reducing policies on firm survival, financial performance, and new drug introductions in the research‐based pharmaceutical industry D Filson, N Masia Managerial and Decision Economics 28 (4‐5), 329-351, 2007 | 12 | 2007 |
| Per-patient-per-month drug costs in Medicare Part D protected classes L Mucha, NA Masia, KJ Axelsen Pharmacoeconomics 24, 79-84, 2006 | 12 | 2006 |
| Effects of medicaid access restrictions on statin utilisation for patients treated by physicians practising in poor and minority neighbourhoods AE Headen, NA Masia, KJ Axelsen Pharmacoeconomics 24, 41-53, 2006 | 9 | 2006 |
| Pharmaceutical innovation: lowering the price of good health NA Masia Economic Realities in Health Care Policy 2 (2), 3-13, 2002 | 7 | 2002 |
| Essays on the political economy of government spending. NA Masia | 5 | 1997 |
| Reconciling differences in Federal and private sector pay comparisons M Musell, N Masia Public Budgeting & Finance 18 (1), 68-77, 1998 | 4 | 1998 |
| Income Differences Between Locations of 340B Entities and Contract Pharmacies N Masia The American Journal of Managed Care, 2023 | 1 | 2023 |
| The Effect of R&D Scale on the Probability of Long-term Financial Success in the Research-Based Pharmaceutical Industry D Filson, N Masia Working paper, Claremont Graduate University, 2004 | 1 | 2004 |
| MD2 PER-PATIENT-PER-MONTH DRUG COSTS IN MEDICARE PART D PROTECTED CLASSES L Mucha, KJ Axelsen, N Masia Value in Health 3 (10), A4, 2007 | | 2007 |
